Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serplulimab + Chemo + Targeted Therapy in Advanced CRC (VICTORY CRC)
NCT06521866Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Mar 2025
- Primary completion
- Aug 2026
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of serplulimab in colorectal cancer (CRC) (4 arms), sponsored by Fudan University. Primary endpoint: Progression-Free Survival at 2 years. Started Mar 2025; status: recruiting.
02
Drugs
serplulimab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06521866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06521866.